{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T21:51:33Z","timestamp":1791409893070,"version":"4.3.3"},"reference-count":185,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,7,29]],"date-time":"2026-07-29T00:00:00Z","timestamp":1785283200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100007480","name":"Universidad de Castilla-La Mancha","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100007480","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Bioorganic Chemistry"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1016\/j.bioorg.2026.110295","type":"journal-article","created":{"date-parts":[[2026,7,25]],"date-time":"2026-07-25T15:07:23Z","timestamp":1784992043000},"page":"110295","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Guanidine-based drugs in cancer therapy"],"prefix":"10.1016","volume":"181","author":[{"given":"Almudena","family":"del Campo-Balguer\u00edas","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alberto","family":"Oca\u00f1a","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Iv\u00e1n","family":"Bravo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlos","family":"Alonso-Moreno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.bioorg.2026.110295_bb0005","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1055\/s-2006-926325","article-title":"Guanidines in organic synthesis","author":"Ishikawa","year":"2006","journal-title":"Synthesis"},{"key":"10.1016\/j.bioorg.2026.110295_bb0010","doi-asserted-by":"crossref","first-page":"5651","DOI":"10.1002\/chem.200900508","article-title":"Solid-state structure of free base guanidine achieved at last","volume":"15","author":"Yamada","year":"2009","journal-title":"Chem. A Eur. J."},{"key":"10.1016\/j.bioorg.2026.110295_bb0015","doi-asserted-by":"crossref","DOI":"10.32931\/io2030r","article-title":"Guanidine: a simple molecule with great potential: from catalysts to biocides and molecular glues","author":"Drozdov","year":"2021","journal-title":"INEOS Open"},{"key":"10.1016\/j.bioorg.2026.110295_bb0020","doi-asserted-by":"crossref","first-page":"11608","DOI":"10.1021\/jp407339v","article-title":"Non-covalent interactions: complexes of guanidinium with DNA and RNA nucleobases","volume":"117","author":"Blanco","year":"2013","journal-title":"J. Phys. Chem. B"},{"key":"10.1016\/j.bioorg.2026.110295_bb0025","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/S0010-8545(00)00389-1","article-title":"The coordination chemistry of guanidines and guanidinates","volume":"214","author":"Bailey","year":"2001","journal-title":"Coord. Chem. Rev."},{"key":"10.1016\/j.bioorg.2026.110295_bb0030","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1007\/s11224-008-9377-9","article-title":"Hydrogen bonds and ionic interactions in guanidine\/guanidinium complexes: a computational case study","volume":"19","author":"Rozas","year":"2008","journal-title":"Struct. Chem."},{"key":"10.1016\/j.bioorg.2026.110295_bb0035","doi-asserted-by":"crossref","first-page":"3406","DOI":"10.1039\/C4CS00013G","article-title":"Guanidines: from classical approaches to efficient catalytic syntheses","volume":"43","author":"Alonso-Moreno","year":"2014","journal-title":"Chem. Soc. Rev."},{"key":"10.1016\/j.bioorg.2026.110295_bb0040","doi-asserted-by":"crossref","DOI":"10.1016\/j.bioorg.2023.106600","article-title":"Synthetic and natural guanidine derivatives as antitumor and antimicrobial agents: a review","volume":"138","author":"Gomes","year":"2023","journal-title":"Bioorg. Chem."},{"key":"10.1016\/j.bioorg.2026.110295_bb0045","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1002\/med.21529","article-title":"Therapeutic potential of pteridine derivatives: a comprehensive review","volume":"39","author":"Carmona-Mart\u00ednez","year":"2019","journal-title":"Med. Res. Rev."},{"key":"10.1016\/j.bioorg.2026.110295_bb0050","series-title":"Guanidines: Historical, Biological, Biochemical, and Clinical Aspects of the Naturally Occurring Guanidino Compounds","author":"Mori","year":"2013"},{"key":"10.1016\/j.bioorg.2026.110295_bb0055","doi-asserted-by":"crossref","first-page":"1382","DOI":"10.1039\/c2np20071f","article-title":"The chemistry and biology of organic guanidine derivatives","volume":"29","author":"Berlinck","year":"2012","journal-title":"Nat. Prod. Rep."},{"key":"10.1016\/j.bioorg.2026.110295_bb0060","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2021.113293","article-title":"Antimicrobial drugs bearing guanidine moieties: a review","volume":"216","author":"Kim","year":"2021","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.bioorg.2026.110295_bb0065","series-title":"Guanidines as Reagents and Catalysts I. Top. Heterocycl. Chem.","volume":"vol. 51","author":"Selig","year":"2017"},{"key":"10.1016\/j.bioorg.2026.110295_bb0070","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0040410","article-title":"A study on the effect of surface lysine to arginine mutagenesis on protein stability and structure using green fluorescent protein","volume":"7","author":"Sokalingam","year":"2012","journal-title":"PLoS One"},{"key":"10.1016\/j.bioorg.2026.110295_bb0075","series-title":"Use of Guanidine Compounds in the Treatment of Neglected Tropical Diseases","author":"Do","year":"2014"},{"key":"10.1016\/j.bioorg.2026.110295_bb0080","doi-asserted-by":"crossref","first-page":"1417","DOI":"10.1517\/13543770903216675","article-title":"Biological activities of guanidine compounds","volume":"19","author":"Saczewski","year":"2009","journal-title":"Expert Opin. Ther. Pat."},{"key":"10.1016\/j.bioorg.2026.110295_bb0085","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1002\/jlac.18611180203","article-title":"Untersuchungen \u00fcber die chemischen Beziehungen zwischen Guanin, Xanthin, Theobromin, Caffe\u00efn und Kreatinin","volume":"118","author":"Strecker","year":"1861","journal-title":"Justus Liebigs Ann. Chem."},{"key":"10.1016\/j.bioorg.2026.110295_bb0090","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1007\/BF02734659","article-title":"Biochemistry and Neurotoxicology of Guanidino compounds history and recent advances","volume":"22","author":"Mori","year":"1987","journal-title":"Pavlov. J. Biol. Sci."},{"key":"10.1016\/j.bioorg.2026.110295_bb0095","doi-asserted-by":"crossref","first-page":"2075","DOI":"10.2165\/00003495-200262140-00008","article-title":"Rosuvastatin","volume":"62","author":"Carswell","year":"2002","journal-title":"Drugs"},{"key":"10.1016\/j.bioorg.2026.110295_bb0100","series-title":"Side Eff. Drugs Annu.","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1016\/S0378-6080(05)80086-8","article-title":"Antihypertensive drugs","volume":"vol. 14","author":"Steiner","year":"1990"},{"key":"10.1016\/j.bioorg.2026.110295_bb0105","article-title":"Imatinib: a breakthrough of targeted therapy in cancer","volume":"2014","author":"Iqbal","year":"2014","journal-title":"Chemother. Res. Pract."},{"key":"10.1016\/j.bioorg.2026.110295_bb0110","doi-asserted-by":"crossref","first-page":"992","DOI":"10.1056\/NEJM197811022991806","article-title":"Cimetidine","volume":"299","author":"Finkelstein","year":"1978","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.bioorg.2026.110295_bb0115","doi-asserted-by":"crossref","first-page":"4398","DOI":"10.1021\/cr800449m","article-title":"Synthetic approaches to the neuraminidase inhibitors zanamivir (Relenza) and oseltamivir phosphate (Tamiflu) for the treatment of influenza","volume":"109","author":"Magano","year":"2009","journal-title":"Chem. Rev."},{"key":"10.1016\/j.bioorg.2026.110295_bb0120","series-title":"Side Eff. Drugs Annu.","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1016\/bs.seda.2015.08.008","article-title":"Chapter 28 - Antiprotozoal drugs","volume":"vol. 37","author":"Thurston","year":"2015"},{"key":"10.1016\/j.bioorg.2026.110295_bb0125","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1586\/eri.11.174","article-title":"Peramivir for the treatment of influenza","volume":"10","author":"Shetty","year":"2012","journal-title":"Expert Rev. Anti Infect. Ther."},{"key":"10.1016\/j.bioorg.2026.110295_bb0130","doi-asserted-by":"crossref","first-page":"71","DOI":"10.3851\/IMP1688","article-title":"Laninamivir and its prodrug, CS-8958: long-acting neuraminidase inhibitors for the treatment of influenza","volume":"21","author":"Yamashita","year":"2010","journal-title":"Antivir. Chem. Chemother."},{"key":"10.1016\/j.bioorg.2026.110295_bb0135","doi-asserted-by":"crossref","first-page":"3682","DOI":"10.3390\/molecules30183682","article-title":"Guanidino-aryl derivatives: binding to DNA, RNA and G-quadruplex structure and antimetabolic activity","volume":"30","author":"Margeti\u0107","year":"2025","journal-title":"Molecules"},{"key":"10.1016\/j.bioorg.2026.110295_bb0140","doi-asserted-by":"crossref","first-page":"7062","DOI":"10.1039\/C8DT05030A","article-title":"Recent advances in self-assembled amidinium and guanidinium frameworks","volume":"48","author":"White","year":"2019","journal-title":"Dalton Trans."},{"key":"10.1016\/j.bioorg.2026.110295_bb0145","doi-asserted-by":"crossref","DOI":"10.1002\/ange.202416348","article-title":"Guanidinium-stapled helical peptides for targeting protein-protein interactions","volume":"137","author":"Perdriau","year":"2025","journal-title":"Angew. Chem."},{"key":"10.1016\/j.bioorg.2026.110295_bb0150","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1517\/17460441.2013.857308","article-title":"Novel approaches to screening guanidine derivatives","volume":"9","author":"Rauf","year":"2014","journal-title":"Expert Opin. Drug Discovery"},{"key":"10.1016\/j.bioorg.2026.110295_bb0155","doi-asserted-by":"crossref","first-page":"700","DOI":"10.1021\/jm301614w","article-title":"Aminoalkyl derivatives of guanidine diaromatic minor groove binders with antiprotozoal activity","volume":"56","author":"McKeever","year":"2013","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bioorg.2026.110295_bb0160","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-017-08749-6","article-title":"Identification, synthesis and biological activity of alkyl-guanidine oligomers as potent antibacterial agents","volume":"7","author":"Zamperini","year":"2017","journal-title":"Sci. Rep."},{"key":"10.1016\/j.bioorg.2026.110295_bb0165","doi-asserted-by":"crossref","first-page":"2492","DOI":"10.1016\/j.bbamem.2014.05.022","article-title":"Guanidino groups greatly enhance the action of antimicrobial peptidomimetics against bacterial cytoplasmic membranes","volume":"1838","author":"Andreev","year":"2014","journal-title":"Biochim. Biophys. Acta Biomembr."},{"key":"10.1016\/j.bioorg.2026.110295_bb0170","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1016\/j.parint.2012.05.015","article-title":"Nuclease activity and ultrastructural effects of new sulfonamides with anti-leishmanial and trypanocidal activities","volume":"61","author":"Bilbao-Ramos","year":"2012","journal-title":"Parasitol. Int."},{"key":"10.1016\/j.bioorg.2026.110295_bb0175","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1002\/cmdc.202000763","article-title":"Development of an improved guanidine-based Rac1 inhibitor with in vivo activity against non-small cell lung cancer","volume":"16","author":"Ciarlantini","year":"2021","journal-title":"ChemMedChem"},{"key":"10.1016\/j.bioorg.2026.110295_bb0180","doi-asserted-by":"crossref","first-page":"1357","DOI":"10.3390\/biomedicines10061357","article-title":"Rac1 as a target to treat dysfunctions and cancer of the bladder","volume":"10","author":"Sauzeau","year":"2022","journal-title":"Biomedicines"},{"key":"10.1016\/j.bioorg.2026.110295_bb0185","article-title":"Synthesis, antimicrobial activities, and model of action of indolyl derivatives containing amino-guanidinium moieties","volume":"30","author":"Li","year":"2025","journal-title":"Molecules"},{"key":"10.1016\/j.bioorg.2026.110295_bb0190","doi-asserted-by":"crossref","DOI":"10.3390\/ijms241813820","article-title":"Guanylation reactions for the rational design of cancer therapeutic agents","volume":"24","author":"Del Campo-Balguer\u00edas","year":"2023","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.bioorg.2026.110295_bb0195","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2018.01697","article-title":"Potential mechanisms connecting purine metabolism and cancer therapy","volume":"9","author":"Yin","year":"2018","journal-title":"Front. Immunol."},{"key":"10.1016\/j.bioorg.2026.110295_bb0200","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1007\/BF01119794","article-title":"The purine path to chemotherapy","volume":"9","author":"Elion","year":"1989","journal-title":"Biosci. Rep."},{"key":"10.1016\/j.bioorg.2026.110295_bb0205","series-title":"Arb. Aus Dem Pharm. Inst. Univ. Berl. Erster Band","first-page":"40","article-title":"Der Aufbau der Xanthinbasen aus der Cyanessigs\u00e4ure. Synthese des Hypoxanthins und Adenins","author":"Traube","year":"1904"},{"key":"10.1016\/j.bioorg.2026.110295_bb0210","unstructured":"Drugs@FDA: FDA-Approved Drugs n.d. https:\/\/www.accessdata.fda.gov\/scripts\/cder\/daf\/index.cfm?event=BasicSearch.process (accessed May 9, 2025)."},{"key":"10.1016\/j.bioorg.2026.110295_bb0215","doi-asserted-by":"crossref","DOI":"10.1002\/pbc.31410","article-title":"A soaring price, a silent fight: Thioguanine portends new access barriers to life-saving treatments for children with cancer","volume":"72","author":"Dickens","year":"2025","journal-title":"Pediatr. Blood Cancer"},{"key":"10.1016\/j.bioorg.2026.110295_bb0220","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1038\/nm0297-136","article-title":"Clinical investigators as critical determinants in pharmaceutical innovation","volume":"3","author":"Flowers","year":"1997","journal-title":"Nat. Med."},{"key":"10.1016\/j.bioorg.2026.110295_bb0225","first-page":"308","article-title":"Radionuclide diagnosis and therapy of neural crest tumors using iodine-131 metaiodobenzylguanidine","volume":"8","author":"Hoefnagel","year":"1987","journal-title":"J. Nucl. Med."},{"key":"10.1016\/j.bioorg.2026.110295_bb0230","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000023284","article-title":"Clinical efficacy and safety of 6-thioguanine in the treatment of childhood acute lymphoblastic leukemia: a protocol for systematic review and meta-analysis","volume":"99","author":"Chen","year":"2020","journal-title":"Medicine"},{"key":"10.1016\/j.bioorg.2026.110295_bb0235","doi-asserted-by":"crossref","DOI":"10.1186\/s12885-022-09522-3","volume":"22","author":"Toksvang","year":"2022","journal-title":"BMC Cancer"},{"key":"10.1016\/j.bioorg.2026.110295_bb0240","first-page":"3955","article-title":"Utilization of 2\u2019-deoxy-6-thioguanosine S\u2019-triphosphate in DNA synthesis in vitro by DNA polymerase a from calf Thymus1","volume":"39","author":"Yoshida","year":"1979","journal-title":"Cancer Res."},{"key":"10.1016\/j.bioorg.2026.110295_bb0245","first-page":"3721","article-title":"Evidence for a connection between the mismatch repair system and the G2 cell cycle checkpoint1","volume":"55","author":"Hawn","year":"1995","journal-title":"Cancer Res."},{"key":"10.1016\/j.bioorg.2026.110295_bb0250","doi-asserted-by":"crossref","first-page":"1331","DOI":"10.1101\/gad.294404","article-title":"Mismatch repair-dependent G2 checkpoint induced by low doses of SN1 type methylating agents requires the ATR kinase","volume":"18","author":"Stojic","year":"2004","journal-title":"Genes Dev."},{"key":"10.1016\/j.bioorg.2026.110295_bb0255","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1038\/nrd1930","article-title":"Epigenetic therapy of cancer: past, present and future","volume":"5","author":"Yoo","year":"2006","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.bioorg.2026.110295_bb0260","doi-asserted-by":"crossref","first-page":"820","DOI":"10.1200\/JCO.2011.35.6394","article-title":"New comprehensive cytogenetic scoring system for primary myelodysplastic syndromes (MDS) and oligoblastic acute myeloid leukemia after MDS derived from an international database merge","volume":"30","author":"Schanz","year":"2012","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.bioorg.2026.110295_bb0265","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1200\/JCO.2009.23.9178","article-title":"Multicenter, phase II study of decitabine for the first-line treatment of older patients with acute myeloid leukemia","volume":"28","author":"Cashen","year":"2010","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.bioorg.2026.110295_bb0270","series-title":"Small Molecules in Oncology","volume":"vol. 211","year":"2018"},{"key":"10.1016\/j.bioorg.2026.110295_bb0275","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/j.clml.2014.04.010","article-title":"Comparison between decitabine and azacitidine for the treatment of myelodysplastic syndrome: a meta-analysis with 1,392 participants","volume":"15","author":"Xie","year":"2015","journal-title":"Clin. Lymphoma Myeloma Leuk."},{"key":"10.1016\/j.bioorg.2026.110295_bb0280","doi-asserted-by":"crossref","first-page":"1794","DOI":"10.1002\/cncr.21792","article-title":"Decitabine improves patient outcomes in myelodysplastic syndromes: results of a phase III randomized study","volume":"106","author":"Kantarjian","year":"2006","journal-title":"Cancer"},{"key":"10.1016\/j.bioorg.2026.110295_bb0285","doi-asserted-by":"crossref","first-page":"2060","DOI":"10.1135\/cccc19642060","article-title":"Nucleic acids components and their analogues. LI. Synthesis of 1-glycosyl derivatives of 5-azauracil and 5-azacytosine","volume":"29","author":"P\u00edskala","year":"1964","journal-title":"Collect. Czechoslov. Chem. Commun."},{"key":"10.1016\/j.bioorg.2026.110295_bb0290","first-page":"339","article-title":"Effect of 5-aza-2\u2032-deoxycytidine against leukemic and hemopoietic tissues in AKR mice","volume":"15","author":"Sorm","year":"1968","journal-title":"Neoplasma"},{"key":"10.1016\/j.bioorg.2026.110295_bb0295","doi-asserted-by":"crossref","first-page":"237","DOI":"10.7326\/0003-4819-85-2-237","article-title":"5-Azacytidine a new anticancer drug with effectiveness in acute myelogenous leukemia","volume":"85","author":"Hoff","year":"1976","journal-title":"Ann. Intern. Med."},{"key":"10.1016\/j.bioorg.2026.110295_bb0300","first-page":"135","article-title":"DNA methylation inhibitors in the treatment of leukemias, myelodysplastic syndromes and hemoglobinopathies: clinical results and possible mechanisms of action","volume":"249","author":"Lubbert","year":"2000","journal-title":"Curr. Top. Microbiol. Immunol."},{"key":"10.1016\/j.bioorg.2026.110295_bb0305","series-title":"Cellular Differentiation, Cytidine Analogs and DNA Methylation","author":"Jones","year":"1980"},{"key":"10.1016\/j.bioorg.2026.110295_bb0310","doi-asserted-by":"crossref","first-page":"2441","DOI":"10.1200\/JCO.2002.04.044","article-title":"Impact of azacytidine on the quality of life of patients with myelodysplastic syndrome treated in a randomized phase III trial: a cancer and leukemia group B study","volume":"20","author":"Kornblith","year":"2002","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.bioorg.2026.110295_bb0315","doi-asserted-by":"crossref","first-page":"2429","DOI":"10.1200\/JCO.2002.04.117","article-title":"Randomized controlled trial of azacitidine in patients with the myelodysplastic syndrome: a study of the cancer and leukemia group B","volume":"20","author":"Silverman","year":"2002","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.bioorg.2026.110295_bb0320","series-title":"Small Mol. Oncol.","first-page":"159","article-title":"5-Azacytidine\/azacitidine","author":"M\u00fcller","year":"2010"},{"key":"10.1016\/j.bioorg.2026.110295_bb0325","article-title":"Low-dose decitabine augments the activation and anti-tumor immune response of IFN-\u03b3+ CD4+ T cells through enhancing I\u03baB\u03b1 degradation and NF-\u03baB activation","volume":"9","author":"Li","year":"2021","journal-title":"Front. Cell Dev. Biol."},{"key":"10.1016\/j.bioorg.2026.110295_bb0330","first-page":"2760","article-title":"Cytotoxicity and mode of action of 5-azacytidine on LI 210 leukemia1","volume":"30","author":"Li","year":"1970","journal-title":"Cancer Res."},{"key":"10.1016\/j.bioorg.2026.110295_bb0335","doi-asserted-by":"crossref","first-page":"8127","DOI":"10.1158\/0008-5472.CAN-09-0458","article-title":"Azacytidine inhibits RNA methylation at DNMT2 target sites in human cancer cell lines","volume":"69","author":"Schaefer","year":"2009","journal-title":"Cancer Res."},{"key":"10.1016\/j.bioorg.2026.110295_bb0340","doi-asserted-by":"crossref","DOI":"10.1002\/hlca.201800229","article-title":"Label-free quantification of 5-azacytidines directly in the genome","volume":"102","author":"Schiffers","year":"2019","journal-title":"Helv. Chim. Acta"},{"key":"10.1016\/j.bioorg.2026.110295_bb0345","doi-asserted-by":"crossref","DOI":"10.1002\/jcla.23597","article-title":"Azacitidine regulates DNA methylation of GADD45\u03b3 in myelodysplastic syndromes","volume":"35","author":"Yang","year":"2021","journal-title":"J. Clin. Lab. Anal."},{"key":"10.1016\/j.bioorg.2026.110295_bb0350","doi-asserted-by":"crossref","first-page":"1519","DOI":"10.1002\/jps.2600681214","article-title":"Catecholamine analogs as potential antitumor agents","volume":"68","author":"Driscoll","year":"1979","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.bioorg.2026.110295_bb0355","doi-asserted-by":"crossref","DOI":"10.1021\/acs.jnatprod.3c00465","article-title":"Catecholamine derivatives: natural occurrence, structural diversity, and biological activity","author":"Tang","year":"2023","journal-title":"J. Nat. Prod."},{"key":"10.1016\/j.bioorg.2026.110295_bb0360","first-page":"991","article-title":"Levodopa and dopamine analogs: melanin precursors as antitumor agents in experimental human and murine leukemia","volume":"63","author":"Wick","year":"1979","journal-title":"Cancer Treat. Rep."},{"key":"10.1016\/j.bioorg.2026.110295_bb0365","doi-asserted-by":"crossref","first-page":"1018","DOI":"10.3390\/cancers11071018","article-title":"Targeted radionuclide therapy for patients with metastatic pheochromocytoma and paraganglioma: from low-specific-activity to high-specific-activity iodine-131 metaiodobenzylguanidine","volume":"11","author":"Jimenez","year":"2019","journal-title":"Cancers"},{"key":"10.1016\/j.bioorg.2026.110295_bb0370","first-page":"469","article-title":"Radiation dosimetry, pharmacokinetics, and safety of Ultratrace\u2122 iobenguane I-131 in patients with malignant pheochromocytoma\/paraganglioma or metastatic carcinoid","volume":"24","author":"Coleman","year":"2009","journal-title":"Cancer Biother. Radiopharm."},{"key":"10.1016\/j.bioorg.2026.110295_bb0375","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1053\/j.semnuclmed.2011.05.003","article-title":"Radioiodinated metaiodobenzylguanidine (MIBG): radiochemistry, biology, and pharmacology","volume":"41","author":"Vallabhajosula","year":"2011","journal-title":"Semin. Nucl. Med."},{"key":"10.1016\/j.bioorg.2026.110295_bb0380","doi-asserted-by":"crossref","DOI":"10.3389\/fmed.2020.00173","article-title":"MIBG therapy for neuroblastoma: precision achieved with dosimetry, and concern for false responders","volume":"7","author":"Rubio","year":"2020","journal-title":"Front. Med."},{"key":"10.1016\/j.bioorg.2026.110295_bb0385","first-page":"349","article-title":"Radiolabeled adrenergic neuron-blocking agents: adrenomedudary imaging with[1311]iodobenzylguan","volume":"21","author":"Wieland","year":"1980","journal-title":"J. Nucl. Med."},{"key":"10.1016\/j.bioorg.2026.110295_bb0390","first-page":"441","article-title":"Radioiodinated metaiodobenzylguanidine in the diagnosis and therapy of carcinoid tumors","volume":"52","author":"Khan","year":"2008","journal-title":"Q. J. Nucl. Med. Mol. Imaging"},{"key":"10.1016\/j.bioorg.2026.110295_bb0395","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1007\/s11864-020-00787-z","article-title":"Emerging treatments for advanced\/metastatic pheochromocytoma and paraganglioma","volume":"21","author":"Ilanchezhian","year":"2020","journal-title":"Curr. Treat. Options Oncol."},{"key":"10.1016\/j.bioorg.2026.110295_bb0400","doi-asserted-by":"crossref","first-page":"623","DOI":"10.2967\/jnumed.118.217463","article-title":"Efficacy and safety of high-specific-activity 131I-MIBG therapy in patients with advanced pheochromocytoma or paraganglioma","volume":"60","author":"Pryma","year":"2019","journal-title":"J. Nucl. Med."},{"key":"10.1016\/j.bioorg.2026.110295_bb0405","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1053\/j.semnuclmed.2011.05.003","article-title":"Radioiodinated metaiodobenzylguanidine (MIBG): radiochemistry, biology, and pharmacology","volume":"41","author":"Vallabhajosula","year":"2011","journal-title":"Semin. Nucl. Med."},{"key":"10.1016\/j.bioorg.2026.110295_bb0410","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1007\/s40336-020-00392-y","article-title":"Pictorial review of the clinical applications of MIBG in neuroblastoma: current practices","volume":"8","author":"Khalatbari","year":"2020","journal-title":"Clin. Translat. Imaging"},{"key":"10.1016\/j.bioorg.2026.110295_bb0415","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1002\/pbc.25200","article-title":"Nothing but NET: a review of norepinephrine transporter expression and efficacy of 131I-mIBG therapy","volume":"62","author":"Streby","year":"2015","journal-title":"Pediatr. Blood Cancer"},{"key":"10.1016\/j.bioorg.2026.110295_bb0420","doi-asserted-by":"crossref","DOI":"10.3389\/fendo.2018.00277","article-title":"Treatment for patients with malignant pheochromocytomas and paragangliomas: a perspective from the hallmarks of cancer","volume":"9","author":"Jimenez","year":"2018","journal-title":"Front. Endocrinol."},{"key":"10.1016\/j.bioorg.2026.110295_bb0425","doi-asserted-by":"crossref","unstructured":"Kraal KCJM, Dalen EC van, Tytgat GAM, Eck-Smit BLFV. Iodine-131-meta-iodobenzylguanidine therapy for patients with newly diagnosed high-risk neuroblastoma. Cochrane Database Syst. Rev. 2017;2017. Doi: https:\/\/doi.org\/10.1002\/14651858.CD010349.pub2.","DOI":"10.1002\/14651858.CD010349.pub2"},{"key":"10.1016\/j.bioorg.2026.110295_bb0430","series-title":"Full Prescribing Information for AZEDRA","author":"U.S. Food and Drug Administration","year":"2018"},{"key":"10.1016\/j.bioorg.2026.110295_bb0435","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1016\/j.drudis.2020.12.006","article-title":"Folate-mediated one-carbon metabolism: a targeting strategy in cancer therapy","volume":"26","author":"Yang","year":"2021","journal-title":"Drug Discov. Today"},{"key":"10.1016\/j.bioorg.2026.110295_bb0440","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1158\/1535-7163.MCT-06-0343","article-title":"Pemetrexed: biochemical and cellular pharmacology, mechanisms, and clinical applications","volume":"6","author":"Chattopadhyay","year":"2007","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.bioorg.2026.110295_bb0445","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1016\/j.drup.2012.07.002","article-title":"Antifolates in cancer therapy: structure, activity and mechanisms of drug resistance","volume":"15","author":"Gonen","year":"2012","journal-title":"Drug Resist. Updat."},{"key":"10.1016\/j.bioorg.2026.110295_bb0450","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1111\/pde.15327","article-title":"Methotrexate for inflammatory skin disease in pediatric patients: consensus treatment guidelines","volume":"40","author":"Siegfried","year":"2023","journal-title":"Pediatr. Dermatol."},{"key":"10.1016\/j.bioorg.2026.110295_bb0455","article-title":"New drugs and dosage forms","volume":"66","year":"2009","journal-title":"Am. J. Health-Syst. Pharm."},{"key":"10.1016\/j.bioorg.2026.110295_bb0460","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1053\/sonc.2002.37461","article-title":"Molecular, biochemical, and cellular pharmacology of pemetrexed","volume":"29","author":"Goldman","year":"2002","journal-title":"Semin. Oncol."},{"key":"10.1016\/j.bioorg.2026.110295_bb0465","doi-asserted-by":"crossref","first-page":"9938","DOI":"10.1021\/jo030248h","article-title":"A new and efficient synthesis of pyrrolo[2,3-d]pyrimidine anticancer agents: Alimta (LY231514, MTA), homo-alimta, TNP-351, and some aryl 5-substituted pyrrolo[2,3-d]pyrimidines","volume":"68","author":"Taylor","year":"2003","journal-title":"J. Org. Chem."},{"key":"10.1016\/j.bioorg.2026.110295_bb0470","doi-asserted-by":"crossref","first-page":"1343","DOI":"10.1016\/j.clinthera.2005.09.010","article-title":"Pemetrexed: a multitargeted antifolate","volume":"27","author":"Rollins","year":"2005","journal-title":"Clin. Ther."},{"key":"10.1016\/j.bioorg.2026.110295_bb0475","first-page":"3687","article-title":"The mechanism of transport of the multitargeted antifolate (MTA) and its cross-resistance pattern in cells with markedly impaired transport of methotrexate 1","volume":"6","author":"Zhao","year":"2000","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.bioorg.2026.110295_bb0480","doi-asserted-by":"crossref","first-page":"S51","DOI":"10.3816\/CLC.2004.s.003","article-title":"Pharmacology and mechanism of action of pemetrexed","volume":"5","author":"Adjei","year":"2004","journal-title":"Clin. Lung Cancer"},{"key":"10.1016\/j.bioorg.2026.110295_bb0485","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3390\/antibiotics3010001","article-title":"Utility of the biosynthetic folate pathway for targets in antimicrobial discovery","volume":"3","author":"Bourne","year":"2014","journal-title":"Antibiotics"},{"key":"10.1016\/j.bioorg.2026.110295_bb0490","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1634\/theoncologist.6-4-363","article-title":"Pemetrexed disodium: a novel antifolate clinically active against multiple solid tumors","volume":"6","author":"Hanauske","year":"2001","journal-title":"Oncologist"},{"key":"10.1016\/j.bioorg.2026.110295_bb0495","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1054\/bjoc.2001.2010","article-title":"Pemetrexed disodium in recurrent locally advanced or metastatic squamous cell carcinoma of the head and neck","volume":"85","author":"Pivot","year":"2001","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.bioorg.2026.110295_bb0500","doi-asserted-by":"crossref","first-page":"1543","DOI":"10.1093\/annonc\/mdg406","article-title":"Phase II study of pemetrexed disodium (Alimta\u00ae) administered with oral folic acid in patients with advanced gastric cancer","volume":"14","author":"Bajetta","year":"2003","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.bioorg.2026.110295_bb0505","doi-asserted-by":"crossref","first-page":"3743","DOI":"10.1002\/cncr.26709","article-title":"Pemetrexed in the treatment of relapsed\/refractory primary central nervous system lymphoma","volume":"118","author":"Raizer","year":"2012","journal-title":"Cancer"},{"key":"10.1016\/j.bioorg.2026.110295_bb0510","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1023\/A:1008305205159","article-title":"Phase II study of the multitargeted antifolate LY231514 (ALIMTA(TM), MTA, pemetrexed disodium) in patients with advanced pancreatic cancer","volume":"11","author":"Miller","year":"2000","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.bioorg.2026.110295_bb0515","doi-asserted-by":"crossref","first-page":"1175","DOI":"10.1023\/A:1008372529239","article-title":"Phase II study of first-line LY231514 (multi-targeted antifolate) in patients with locally advanced or metastatic colorectal cancer: An NCIC Clinical Trials Group study","volume":"10","author":"Cripps","year":"1999","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.bioorg.2026.110295_bb0520","doi-asserted-by":"crossref","first-page":"47","DOI":"10.3816\/CBC.2001.n.010","article-title":"Activity of Pemetrexed (ALIMTA\u00ae, multitargeted antifolate, LY231514) in metastatic breast cancer patients previously treated with an anthracycline and a taxane: an interim analysis","volume":"2","author":"Spielmann","year":"2001","journal-title":"Clin. Breast Cancer"},{"key":"10.1016\/j.bioorg.2026.110295_bb0525","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.freeradbiomed.2021.05.002","article-title":"Properties and reactivity of the folic acid and folate photoproduct 6-formylpterin","volume":"171","author":"Goossens","year":"2021","journal-title":"Free Radic. Biol. Med."},{"key":"10.1016\/j.bioorg.2026.110295_bb0530","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2024.1450418","article-title":"The role of l-leucovorin uptake and metabolism in the modulation of 5-fluorouracil efficacy and antifolate toxicity","volume":"15","author":"Peters","year":"2024","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.bioorg.2026.110295_bb0535","doi-asserted-by":"crossref","first-page":"155","DOI":"10.69613\/k20qe441","article-title":"A revisit on FDA approved anticancer drugs (1949\u20132024): review article","volume":"2","author":"Myla","year":"2024","journal-title":"J Pharma Insights Res"},{"key":"10.1016\/j.bioorg.2026.110295_bb0540","first-page":"1657","article-title":"A quantitative comparison of the antileukemic effectiveness of two folic acid antagonists in mice","volume":"15","author":"Goldin","year":"1955","journal-title":"JNCI J. Natl. Cancer Inst."},{"key":"10.1016\/j.bioorg.2026.110295_bb0545","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1200\/JCO.1993.11.1.5","article-title":"Ode to methotrexate","volume":"11","author":"Bertino","year":"1993","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.bioorg.2026.110295_bb0550","doi-asserted-by":"crossref","first-page":"2692","DOI":"10.1158\/1078-0432.CCR-06-1754","article-title":"A phase 1 study of pralatrexate in combination with paclitaxel or docetaxel in patients with advanced solid tumors","volume":"13","author":"Azzoli","year":"2007","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.bioorg.2026.110295_bb0555","doi-asserted-by":"crossref","first-page":"1271","DOI":"10.1007\/s40264-021-01135-2","article-title":"Mechanisms, management and prevention of pemetrexed-related toxicity","volume":"44","author":"de Rouw","year":"2021","journal-title":"Drug Saf."},{"key":"10.1016\/j.bioorg.2026.110295_bb0560","doi-asserted-by":"crossref","first-page":"1471","DOI":"10.1634\/theoncologist.2015-0164","article-title":"Preventing and managing toxicities of high-dose methotrexate","volume":"21","author":"Howard","year":"2016","journal-title":"Oncologist"},{"key":"10.1016\/j.bioorg.2026.110295_bb0565","doi-asserted-by":"crossref","DOI":"10.1016\/j.ctrv.2021.102218","article-title":"Metastatic colorectal cancer: advances in the folate-fluoropyrimidine chemotherapy backbone","volume":"98","author":"Glimelius","year":"2021","journal-title":"Cancer Treat. Rev."},{"key":"10.1016\/j.bioorg.2026.110295_bb0570","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1200\/JCO.2004.05.188","article-title":"Multicenter phase II study of Nordic fluorouracil and folinic acid bolus schedule combined with oxaliplatin as first-line treatment of metastatic colorectal cancer","volume":"22","author":"S\u00f8rbye","year":"2004","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.bioorg.2026.110295_bb0575","doi-asserted-by":"crossref","first-page":"1338","DOI":"10.1016\/S0959-8049(99)00149-5","article-title":"Oxaliplatin added to the simplified bimonthly leucovorin and 5-fluorouracil regimen as second-line therapy for metastatic colorectal cancer (FOLFOX6)","volume":"35","author":"Maindrault-Goebel","year":"1999","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/j.bioorg.2026.110295_bb0580","doi-asserted-by":"crossref","first-page":"254","DOI":"10.2165\/00003495-199141020-00008","article-title":"Goserelin. A review of its pharmacodynamic and pharmacokinetic properties, and clinical use in sex hormone-related conditions","volume":"41","author":"Chrisp","year":"1991","journal-title":"Drugs"},{"key":"10.1016\/j.bioorg.2026.110295_bb0585","doi-asserted-by":"crossref","first-page":"1485","DOI":"10.1016\/j.clinthera.2006.10.018","article-title":"Luteinizing hormone-releasing hormone agonists in the treatment of prostate cancer: a review of their discovery, development, and place in therapy","volume":"28","author":"Moreau","year":"2006","journal-title":"Clin. Ther."},{"key":"10.1016\/j.bioorg.2026.110295_bb0590","doi-asserted-by":"crossref","first-page":"399","DOI":"10.2174\/1568011033482251","article-title":"GnRH agonists and antagonists in cancer therapy","volume":"3","author":"Chengalvala","year":"2003","journal-title":"Curr. Med. Chem. Anti-Cancer Agents"},{"key":"10.1016\/j.bioorg.2026.110295_bb0595","doi-asserted-by":"crossref","DOI":"10.20892\/j.issn.2095-3941.2024.0139","article-title":"Luteinizing hormone-releasing hormone receptor agonists and antagonists in prostate cancer: effects on long-term survival and combined therapy with next-generation hormonal agents","volume":"21","author":"Zhao","year":"2024","journal-title":"Cancer Biol. Med."},{"key":"10.1016\/j.bioorg.2026.110295_bb0600","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/S0090-4295(02)02396-8","article-title":"Eligard: leuprolide acetate in a novel sustained-release delivery system","volume":"61","author":"Sartor","year":"2003","journal-title":"Urology"},{"key":"10.1016\/j.bioorg.2026.110295_bb0605","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1055\/s-2007-1018831","article-title":"The use of GnRH agonists in breast and gynecologic cancers","volume":"11","author":"Gordon","year":"2008","journal-title":"Semin. Reprod. Endocrinol."},{"key":"10.1016\/j.bioorg.2026.110295_bb0610","unstructured":"U.S. Food and Drug Administration. Trelstar (Triptorelin pamoate) Drugs@FDA: FDA-Approved Drugs n.d. https:\/\/www.accessdata.fda.gov\/scripts\/cder\/daf\/index.cfm?event=overview.process&ApplNo=020715 (accessed May 11, 2025)."},{"key":"10.1016\/j.bioorg.2026.110295_bb0615","doi-asserted-by":"crossref","first-page":"8798","DOI":"10.1021\/acs.joc.0c00599","article-title":"Environmentally friendly SPPS II: scope of green Fmoc removal protocol using NaOH and its application for synthesis of commercial drug triptorelin","volume":"85","author":"P\u0159ibylka","year":"2020","journal-title":"J. Org. Chem."},{"key":"10.1016\/j.bioorg.2026.110295_bb0620","doi-asserted-by":"crossref","first-page":"2854S","DOI":"10.1093\/jn\/134.10.2854S","article-title":"Production of arginine by fermentation","volume":"134","author":"Utagawa","year":"2004","journal-title":"J. Nutr."},{"key":"10.1016\/j.bioorg.2026.110295_bb0625","unstructured":"U.S. Food and Drug Administration. Zoladex (goserelin acetate implant) - Drugs@FDA: FDA-Approved Drugs n.d. https:\/\/www.accessdata.fda.gov\/scripts\/cder\/daf\/index.cfm?event=overview.process&ApplNo=019726 (accessed May 11, 2025)."},{"key":"10.1016\/j.bioorg.2026.110295_bb0630","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1159\/000070142","article-title":"3-month formulation of goserelin acetate (\u2018Zoladex\u2019 10.8-mg depot) in advanced prostate cancer: results from an Italian, Open, multicenter trial","volume":"70","author":"Fontana","year":"2003","journal-title":"Urol. Int."},{"key":"10.1016\/j.bioorg.2026.110295_bb0635","doi-asserted-by":"crossref","first-page":"2639","DOI":"10.2165\/00003495-200565180-00011","article-title":"Goserelin","volume":"65","author":"Cheer","year":"2005","journal-title":"Drugs"},{"key":"10.1016\/j.bioorg.2026.110295_bb0640","doi-asserted-by":"crossref","first-page":"1249","DOI":"10.1080\/14737140.2018.1527688","article-title":"A comprehensive review of protein kinase inhibitors for cancer therapy","volume":"18","author":"Kannaiyan","year":"2018","journal-title":"Expert Rev. Anticancer Ther."},{"key":"10.1016\/j.bioorg.2026.110295_bb0645","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1016\/S0968-0004(02)02179-5","article-title":"Evolution of protein kinase signaling from yeast to man","volume":"27","author":"Manning","year":"2002","journal-title":"Trends Biochem. Sci."},{"key":"10.1016\/j.bioorg.2026.110295_bb0650","doi-asserted-by":"crossref","first-page":"1780","DOI":"10.1172\/JCI76094","article-title":"Targeting cancer with kinase inhibitors","volume":"125","author":"Gross","year":"2015","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.bioorg.2026.110295_bb0655","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1038\/s41573-021-00252-y","article-title":"Trends in kinase drug discovery: targets, indications and inhibitor design","volume":"20","author":"Attwood","year":"2021","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.bioorg.2026.110295_bb0660","doi-asserted-by":"crossref","first-page":"1395","DOI":"10.4155\/fmc.09.115","article-title":"Interview with J\u00fcrg Zimmermann, global head of oncology & exploratory chemistry at Novartis","volume":"1","author":"Zimmermann","year":"2009","journal-title":"Future Med. Chem."},{"key":"10.1016\/j.bioorg.2026.110295_bb0665","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.1021\/acs.jmedchem.1c00963","article-title":"Small molecule kinase inhibitor drugs (1995\u20132021): medical indication, pharmacology, and synthesis","volume":"65","author":"Ayala-Aguilera","year":"2022","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bioorg.2026.110295_bb0670","doi-asserted-by":"crossref","first-page":"S77","DOI":"10.1016\/S0959-8049(02)80607-4","article-title":"Imatinib: the first 3 years","volume":"38","author":"Capdeville","year":"2002","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/j.bioorg.2026.110295_bb0675","doi-asserted-by":"crossref","first-page":"S28","DOI":"10.1016\/S0959-8049(02)80600-1","article-title":"Pharmacology of imatinib (STI571)","volume":"38","author":"Buchdunger","year":"2002","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/j.bioorg.2026.110295_bb0680","doi-asserted-by":"crossref","first-page":"636","DOI":"10.1093\/jnci\/djr062","article-title":"Accelerated approval of oncology products: the Food and Drug Administration experience","volume":"103","author":"Johnson","year":"2011","journal-title":"JNCI J. Natl. Cancer Inst."},{"key":"10.1016\/j.bioorg.2026.110295_bb0685","doi-asserted-by":"crossref","first-page":"1956","DOI":"10.1016\/j.clinthera.2008.11.014","article-title":"Nilotinib: a second-generation tyrosine kinase inhibitor for the treatment of chronic myelogenous leukemia","volume":"30","author":"DeRemer","year":"2008","journal-title":"Clin. Ther."},{"key":"10.1016\/j.bioorg.2026.110295_bb0690","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1007\/s40265-015-0533-4","article-title":"Osimertinib: first global approval","volume":"76","author":"Greig","year":"2016","journal-title":"Drugs"},{"key":"10.1016\/j.bioorg.2026.110295_bb0695","doi-asserted-by":"crossref","first-page":"639","DOI":"10.2217\/fon-2021-0923","article-title":"MARIPOSA: phase 3 study of first-line amivantamab + lazertinib versus osimertinib in EGFR-mutant non-small-cell lung cancer","volume":"18","author":"Cho","year":"2022","journal-title":"Future Oncol."},{"key":"10.1016\/j.bioorg.2026.110295_bb0700","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.1039\/D4MD00800F","article-title":"Lazertinib: breaking the mold of third-generation EGFR inhibitors","volume":"16","author":"Patel","year":"2025","journal-title":"RSC Med. Chem."},{"key":"10.1016\/j.bioorg.2026.110295_bb0705","doi-asserted-by":"crossref","first-page":"2436","DOI":"10.1158\/1078-0432.CCR-14-3157","article-title":"FDA approval: ceritinib for the treatment of metastatic anaplastic lymphoma kinase\u2013positive non\u2013small cell lung cancer","volume":"21","author":"Khozin","year":"2015","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.bioorg.2026.110295_bb0710","doi-asserted-by":"crossref","unstructured":"Markham A. Brigatinib: First Global Approval. Drugs 2017;77:1131\u20135. Doi: https:\/\/doi.org\/10.1007\/s40265-017-0776-3.","DOI":"10.1007\/s40265-017-0776-3"},{"key":"10.1016\/j.bioorg.2026.110295_bb0715","doi-asserted-by":"crossref","first-page":"4760","DOI":"10.1158\/1078-0432.CCR-15-1185","article-title":"FDA approval: palbociclib for the treatment of postmenopausal patients with estrogen receptor\u2013positive, HER2-negative metastatic breast cancer","volume":"21","author":"Beaver","year":"2015","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.bioorg.2026.110295_bb0720","doi-asserted-by":"crossref","first-page":"2999","DOI":"10.1158\/1078-0432.CCR-17-2369","article-title":"FDA approval: Ribociclib for the treatment of postmenopausal women with hormone receptor\u2013positive, HER2-negative advanced or metastatic breast cancer","volume":"24","author":"Shah","year":"2018","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.bioorg.2026.110295_bb0725","doi-asserted-by":"crossref","first-page":"2063","DOI":"10.1007\/s40265-017-0840-z","article-title":"Abemaciclib: first global approval","volume":"77","author":"Kim","year":"2017","journal-title":"Drugs"},{"key":"10.1016\/j.bioorg.2026.110295_bb0730","doi-asserted-by":"crossref","DOI":"10.1016\/j.tranon.2021.101206","article-title":"Concerning FDA approval of trilaciclib (Cosela) in extensive-stage small-cell lung cancer","volume":"14","author":"Powell","year":"2021","journal-title":"Transl. Oncol."},{"key":"10.1016\/j.bioorg.2026.110295_bb0735","doi-asserted-by":"crossref","first-page":"1367","DOI":"10.1007\/s40265-013-0095-2","article-title":"Dabrafenib: first global approval","volume":"73","author":"Ballantyne","year":"2013","journal-title":"Drugs"},{"key":"10.1016\/j.bioorg.2026.110295_bb0740","doi-asserted-by":"crossref","first-page":"1277","DOI":"10.1007\/s40265-018-0963-x","article-title":"Encorafenib and binimetinib: first global approvals","volume":"78","author":"Shirley","year":"2018","journal-title":"Drugs"},{"key":"10.1016\/j.bioorg.2026.110295_bb0745","doi-asserted-by":"crossref","first-page":"1719","DOI":"10.1007\/s40265-019-01205-x","article-title":"Fedratinib: first approval","volume":"79","author":"Blair","year":"2019","journal-title":"Drugs"},{"key":"10.1016\/j.bioorg.2026.110295_bb0750","doi-asserted-by":"crossref","first-page":"784","DOI":"10.1016\/j.phrs.2016.07.038","article-title":"Janus kinase (JAK) inhibitors in the treatment of inflammatory and neoplastic diseases","volume":"111","author":"Roskoski","year":"2016","journal-title":"Pharmacol. Res."},{"key":"10.1016\/j.bioorg.2026.110295_bb0755","doi-asserted-by":"crossref","first-page":"82","DOI":"10.12688\/f1000research.13167.1","article-title":"JAK inhibitors for the treatment of myeloproliferative neoplasms and other disorders","volume":"7","author":"Vainchenker","year":"2018","journal-title":"F1000Research"},{"key":"10.1016\/j.bioorg.2026.110295_bb0760","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1007\/s40265-022-01718-y","article-title":"Pacritinib: first approval","volume":"82","author":"Lamb","year":"2022","journal-title":"Drugs"},{"key":"10.1016\/j.bioorg.2026.110295_bb0765","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41408-024-01029-3","article-title":"Momelotinib for myelofibrosis: our 14 years of experience with 100 clinical trial patients and recent FDA approval","volume":"14","author":"Tefferi","year":"2024","journal-title":"Blood Cancer J."},{"key":"10.1016\/j.bioorg.2026.110295_bb0770","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1007\/s11912-007-0007-2","article-title":"Pazopanib: a novel multitargeted tyrosine kinase inhibitor","volume":"9","author":"Sonpavde","year":"2007","journal-title":"Curr. Oncol. Rep."},{"key":"10.1016\/j.bioorg.2026.110295_bb0775","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1200\/JCO.2009.23.9764","article-title":"Pazopanib in locally advanced or metastatic renal cell carcinoma: results of a randomized phase III trial","volume":"28","author":"Sternberg","year":"2010","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.bioorg.2026.110295_bb0780","first-page":"935","article-title":"Approval summary for imatinib mesylate capsules in the treatment of chronic myelogenous leukemia","volume":"8","author":"Cohen","year":"2002","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.bioorg.2026.110295_bb0785","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1007\/s10147-006-0579-0","article-title":"Gastrointestinal stromal tumor (GIST) and imatinib","volume":"11","author":"Kubota","year":"2006","journal-title":"Int. J. Clin. Oncol."},{"key":"10.1016\/j.bioorg.2026.110295_bb0790","doi-asserted-by":"crossref","first-page":"1038","DOI":"10.1056\/NEJM200104053441402","article-title":"Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome","volume":"344","author":"Druker","year":"2001","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.bioorg.2026.110295_bb0795","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1056\/NEJMoa020150","article-title":"Response to imatinib mesylate in patients with chronic myeloproliferative diseases with rearrangements of the platelet-derived growth factor receptor Beta","volume":"347","author":"Apperley","year":"2002","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.bioorg.2026.110295_bb0800","doi-asserted-by":"crossref","first-page":"659","DOI":"10.7150\/jca.88555","article-title":"Imatinib inhibits oral squamous cell carcinoma by suppressing the PI3K\/AKT\/mTOR signaling pathway","volume":"15","author":"Ma","year":"2024","journal-title":"J. Cancer"},{"key":"10.1016\/j.bioorg.2026.110295_bb0805","doi-asserted-by":"crossref","DOI":"10.1016\/j.jmb.2021.167349","article-title":"Imatinib can act as an allosteric activator of Abl kinase","volume":"434","author":"Xie","year":"2022","journal-title":"J. Mol. Biol."},{"key":"10.1016\/j.bioorg.2026.110295_bb0810","unstructured":"SciFinder. Chem Abstr Serv Am Chem Soc n.d. https:\/\/scifinder.cas.org (accessed April 28, 2025)."},{"key":"10.1016\/j.bioorg.2026.110295_bb0815","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41408-024-01143-2","article-title":"Current status and research directions in acute myeloid leukemia","volume":"14","author":"Kantarjian","year":"2024","journal-title":"Blood Cancer J."},{"key":"10.1016\/j.bioorg.2026.110295_bb0820","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1111\/j.1464-410X.2011.10370.x","article-title":"Long-term efficacy and tolerability of once-yearly histrelin acetate subcutaneous implant in patients with advanced prostate cancer","volume":"109","author":"Shore","year":"2012","journal-title":"BJU Int."},{"key":"10.1016\/j.bioorg.2026.110295_bb0825","doi-asserted-by":"crossref","first-page":"31548","DOI":"10.1039\/D5RA05647K","article-title":"Novel guanidine derivatives as mechanistic scaffolds for anticancer agents: synthesis, characterization, DNA-binding, and computational studies","volume":"15","author":"Zaman","year":"2025","journal-title":"RSC Adv."},{"key":"10.1016\/j.bioorg.2026.110295_bb0830","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1039\/B603089K","article-title":"Molecular recognition of oxoanions based on guanidinium receptors","volume":"36","author":"Blondeau","year":"2007","journal-title":"Chem. Soc. Rev."},{"key":"10.1016\/j.bioorg.2026.110295_bb0835","doi-asserted-by":"crossref","DOI":"10.1016\/j.bmcl.2022.128971","article-title":"A guanidinium group is an effective mimic of the tertiary carbocation formed by isopentenyl diphosphate isomerase","volume":"75","author":"Zhuang","year":"2022","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"10.1016\/j.bioorg.2026.110295_bb0840","doi-asserted-by":"crossref","DOI":"10.1002\/cctc.202301477","article-title":"Enzyme mimics based on guanidinocalix[4]arene\/nanodiamond hybrid systems with phosphodiesterase activity","volume":"16","author":"Vezzoni","year":"2024","journal-title":"ChemCatChem"},{"key":"10.1016\/j.bioorg.2026.110295_bb0845","doi-asserted-by":"crossref","first-page":"18363","DOI":"10.1021\/acsami.0c02752","article-title":"Structural superiority of guanidinium-rich, four-armed copolypeptides: role of multiple peptide\u2013membrane interactions in enhancing bacterial membrane perturbation and permeability","volume":"12","author":"Wang","year":"2020","journal-title":"ACS Appl. Mater. Interfaces"},{"key":"10.1016\/j.bioorg.2026.110295_bb0850","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1007\/s40242-022-2204-9","article-title":"Nucleotide recognition by a guanidinocalixarene receptor in aqueous solution","volume":"39","author":"Geng","year":"2023","journal-title":"Chem. Res. Chin. Univ."},{"key":"10.1016\/j.bioorg.2026.110295_bb0855","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/S0010-8545(02)00256-4","article-title":"Abiotic guanidinium containing receptors for anionic species","volume":"240","author":"Best","year":"2003","journal-title":"Coord. Chem. Rev."},{"key":"10.1016\/j.bioorg.2026.110295_bb0860","doi-asserted-by":"crossref","first-page":"2248","DOI":"10.1111\/cas.14490","article-title":"Supplementation of l-arginine boosts the therapeutic efficacy of anticancer chemoimmunotherapy","volume":"111","author":"Satoh","year":"2020","journal-title":"Cancer Sci."},{"key":"10.1016\/j.bioorg.2026.110295_bb0865","doi-asserted-by":"crossref","DOI":"10.1177\/2050312119865114","article-title":"Metformin as an adjuvant in breast cancer treatment","volume":"7","author":"Roshan","year":"2019","journal-title":"SAGE Open Med."},{"key":"10.1016\/j.bioorg.2026.110295_bb0870","doi-asserted-by":"crossref","first-page":"2184","DOI":"10.1093\/annonc\/mdw410","article-title":"Metformin as an adjuvant treatment for cancer: a systematic review and meta-analysis","volume":"27","author":"Coyle","year":"2016","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.bioorg.2026.110295_bb0875","article-title":"Furmonertinib for EGFR-mutant advanced non-small cell lung cancer: a glittering diamond in the rough of EGFR-TKI","volume":"15","author":"Ding","year":"2024","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.bioorg.2026.110295_bb0880","doi-asserted-by":"crossref","DOI":"10.1177\/17588359211042689","article-title":"Current treatments and future potential of surufatinib in neuroendocrine tumors (NETs)","volume":"13","author":"Xu","year":"2021","journal-title":"Ther. Adv. Med. Oncol."},{"key":"10.1016\/j.bioorg.2026.110295_bb0885","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1080\/14737140.2021.1944110","article-title":"Surufatinib for the treatment of advanced extrapancreatic neuroendocrine tumors","volume":"21","author":"Lu","year":"2021","journal-title":"Expert Rev. Anticancer Ther."},{"key":"10.1016\/j.bioorg.2026.110295_bb0905","doi-asserted-by":"crossref","first-page":"1183","DOI":"10.1016\/S0006-2952(01)00570-6","article-title":"Guanidino-containing drugs in cancer chemotherapy: biochemical and clinical pharmacology3","volume":"61","author":"Ekelund","year":"2001","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.bioorg.2026.110295_bb0910","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1016\/0006-2952(91)90038-7","article-title":"Mitochondrial effects of the guanidino group-containing cytostatic drugs, m-iodobenzylguanidine and methylglyoxal bis (guanylhydrazone)","volume":"42","author":"Loesberg","year":"1991","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.bioorg.2026.110295_bb0915","series-title":"Phenyl-Guanidine Derivatives","author":"Menna","year":"2014"},{"key":"10.1016\/j.bioorg.2026.110295_bb0920","doi-asserted-by":"crossref","first-page":"4397","DOI":"10.1021\/jm300296f","article-title":"High DNA affinity of a series of peptide linked diaromatic guanidinium-like derivatives","volume":"55","author":"Nagle","year":"2012","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bioorg.2026.110295_bb0925","doi-asserted-by":"crossref","DOI":"10.1002\/slct.202202819","article-title":"Synthesis, characterization, biological activity and molecular modeling studies of novel aminoguanidine derivatives","volume":"7","author":"Do\u011fan","year":"2022","journal-title":"ChemistrySelect"},{"key":"10.1016\/j.bioorg.2026.110295_bb0930","doi-asserted-by":"crossref","first-page":"6465","DOI":"10.1021\/jm701207m","article-title":"Amine\u2013guanidine switch: a promising approach to improve DNA binding and antiproliferative activities","volume":"50","author":"Ohara","year":"2007","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bioorg.2026.110295_bb0935","doi-asserted-by":"crossref","first-page":"8267","DOI":"10.1039\/C5RA17920C","article-title":"Phenyl-guanidine derivatives as potential therapeutic agents for glioblastoma multiforme: catalytic syntheses, cytotoxic effects and DNA affinity","volume":"6","author":"Bravo","year":"2016","journal-title":"RSC Adv."},{"key":"10.1016\/j.bioorg.2026.110295_bb0940","doi-asserted-by":"crossref","first-page":"4391","DOI":"10.1158\/1078-0432.CCR-15-2539","article-title":"Polyamine antagonist therapies inhibit neuroblastoma initiation and progression","volume":"22","author":"Evageliou","year":"2016","journal-title":"Clin. Cancer Res."}],"container-title":["Bioorganic Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S004520682600831X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S004520682600831X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T21:11:07Z","timestamp":1791407467000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S004520682600831X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10]]},"references-count":185,"alternative-id":["S004520682600831X"],"URL":"https:\/\/doi.org\/10.1016\/j.bioorg.2026.110295","relation":{},"ISSN":["0045-2068"],"issn-type":[{"value":"0045-2068","type":"print"}],"subject":[],"published":{"date-parts":[[2026,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Guanidine-based drugs in cancer therapy","name":"articletitle","label":"Article Title"},{"value":"Bioorganic Chemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bioorg.2026.110295","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"110295"}}